STOCK TITAN

Royalty Pharma plc (RPRX) Net Income by Year

RPRX

Royalty Pharma plc reported $770.9M in net income in fiscal year 2025. This represents a decrease of 10.2% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $812.0M in net income. The table below carries 8 fiscal years, from 2018 to 2025, and the quarters Royalty Pharma plc has filed alongside them.

FY2025 annual
Net Income $770.9M
YoY -10.2%
5Y CAGR -4.6%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

RPRX Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-K
Net Income$812.0M$770.9M-10.2%$859.0M-24.3%$1.1B+2549.5%$42.8M-93.1%$619.7M-36.4%$975.0M-58.5%$2.3B+70.5%$1.4B

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

RPRX Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income$17.9M-44.4%$294.7M+23.1%$211.2M+1.4%$288.2M-47.0%$32.2M-68.5%$239.3M+4909.4%$208.2M-57.9%$544.0M+654.3%$102.0M-55.2%$4.8M-98.6%$494.3M+208.4%$72.1M-49.4%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Royalty Pharma plc financials

Frequently Asked Questions

What was Royalty Pharma plc's net income in fiscal year 2025?

Royalty Pharma plc reported $770.9M in net income in fiscal year 2025.

How fast is Royalty Pharma plc's net income growing?

Royalty Pharma plc (RPRX) net income fell by 10.2% year over year, from $859.0M to $770.9M in fiscal year 2025.

What is Royalty Pharma plc's net income over the last twelve months?

Royalty Pharma plc (RPRX) reported $812.0M in net income over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 8 fiscal years this page covers, Royalty Pharma plc (RPRX) net income went from $1.4B in fiscal year 2018 to $770.9M in fiscal year 2025.

Royalty Pharma plc (RPRX) reported $17.9M in net income in Q2 2026. This represents a decrease of 44.4% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Royalty Pharma plc (RPRX) reported on that line in every period on record.